Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
P 1 (1)
P 2 (4)

Trial Status

Recruiting5
Unknown1
Not Yet Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07692529Phase 1Not Yet Recruiting

A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia

NCT02863692Recruiting

Registry of the German CLL Study Group

NCT06716658Phase 2Recruiting

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

NCT06530576Phase 2RecruitingPrimary

Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

NCT06530550Phase 2Recruiting

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

NCT07019766RecruitingPrimary

National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia

NCT04453345Phase 2UnknownPrimary

TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL

Showing all 7 trials

Research Network

Activity Timeline